228 related articles for article (PubMed ID: 24507810)
21. [Myelodysplastic syndromes and autoimmunity].
Stalder G; Alberio L; Ribi C
Rev Med Suisse; 2015 Apr; 11(469):820-2, 824-5. PubMed ID: 26040163
[TBL] [Abstract][Full Text] [Related]
22. Altered Th17 cells and Th17/regulatory T-cell ratios indicate the subsequent conversion from undifferentiated connective tissue disease to definitive systemic autoimmune disorders.
Szodoray P; Nakken B; Barath S; Csipo I; Nagy G; El-Hage F; Osnes LT; Szegedi G; Bodolay E
Hum Immunol; 2013 Dec; 74(12):1510-8. PubMed ID: 23974054
[TBL] [Abstract][Full Text] [Related]
23. Autoimmune phenomena in patients with myelodysplastic syndromes.
Enright H; Miller W
Leuk Lymphoma; 1997 Feb; 24(5-6):483-9. PubMed ID: 9086438
[TBL] [Abstract][Full Text] [Related]
24. Immunologic abnormalities in myelodysplastic syndromes.
Hamblin T
Hematol Oncol Clin North Am; 1992 Jun; 6(3):571-86. PubMed ID: 1613007
[TBL] [Abstract][Full Text] [Related]
25. A comprehensive review of myelodysplastic syndrome patients with autoimmune diseases.
Giannouli S; Voulgarelis M
Expert Rev Clin Immunol; 2014 Dec; 10(12):1679-88. PubMed ID: 25308147
[TBL] [Abstract][Full Text] [Related]
26. [Abnormal polarization of T lymphocyte induces negative hematopoietic regulation in myelodysplastic syndromes].
Wu LY; Li X; Chang CK; Ying SX; Pu Q
Zhonghua Xue Ye Xue Za Zhi; 2007 Aug; 28(8):549-54. PubMed ID: 18078133
[TBL] [Abstract][Full Text] [Related]
27. The deviated balance between regulatory T cell and Th17 in autoimmunity.
Jadidi-Niaragh F; Mirshafiey A
Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):727-39. PubMed ID: 22316060
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Fraison JB; Mekinian A; Grignano E; Kahn JE; Arlet JB; Decaux O; Denis G; Buchdahl AL; Omouri M; Maigne G; Aouba A; Leon N; Berthier S; Liozon E; Park S; Gardin C; Lortholary O; Rossignol J; Fenaux P; Fain O; Braun T
Leuk Res; 2016 Apr; 43():13-7. PubMed ID: 26922775
[TBL] [Abstract][Full Text] [Related]
29. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes.
Kiladjian JJ; Bourgeois E; Lobe I; Braun T; Visentin G; Bourhis JH; Fenaux P; Chouaib S; Caignard A
Leukemia; 2006 Mar; 20(3):463-70. PubMed ID: 16408099
[TBL] [Abstract][Full Text] [Related]
30. In vitro effects of IL-2 on NK-activity, clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow patients.
Cortelezzi A; Sarina B; Cattaneo C; Pomati M; Silvestris I; Soligo D; Calori R; Di Stefano M; Hu C; Monza M; Radelli L; Maiolo AT
Leukemia; 1996 Jul; 10(7):1181-9. PubMed ID: 8684000
[TBL] [Abstract][Full Text] [Related]
31. Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study.
Péan de Ponfilly-Sotier M; Jachiet V; Benhamou Y; Lahuna C; De Renzis B; Kottler D; Voillat L; Dimicoli-Salazar S; Banos A; Chauveheid MP; Alexandra JF; Grignano E; Liferman F; Laborde M; Broner J; Michel M; Lambotte O; Laribi K; Venon MD; Dussol B; Martis N; Thepot S; Park S; Couret D; Roux-Sauvat M; Terriou L; Hachulla E; Bally C; Galland J; Allain JS; Parcelier A; Peterlin P; Cohen-Bittan J; Regent A; Ackermann F; Le Guen J; Algrin C; Charles P; Daguindau E; Puechal X; Dunogue B; Blanchard-Delaunay C; Beyne-Rauzy O; Grobost V; Schmidt J; Le Gallou T; Dubos-Lascu G; Sonet A; Denis G; Roy-Peaud F; Fenaux P; Adès L; Fain O; Mekinian A;
Clin Exp Rheumatol; 2022 Jul; 40(7):1336-1342. PubMed ID: 35579092
[TBL] [Abstract][Full Text] [Related]
32. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
33. [Inhibition of hematopoiesis by sera from patients with myelodysplastic syndromes].
Ding R; Liu H; Xu R
Zhonghua Xue Ye Xue Za Zhi; 1999 Oct; 20(10):515-7. PubMed ID: 11721395
[TBL] [Abstract][Full Text] [Related]
34. The Yin and Yang of myelodysplastic syndromes and autoimmunity: The paradox of autoimmune disorders responding to therapies specific for MDS.
Fozza C; La Nasa G; Caocci G
Crit Rev Oncol Hematol; 2019 Oct; 142():51-57. PubMed ID: 31376677
[TBL] [Abstract][Full Text] [Related]
35. Deviation of type I and type II T cells and its negative effect on hematopoiesis in myelodysplastic syndrome.
Wu L; Li X; Chang C; Ying S; He Q; Pu Q
Int J Lab Hematol; 2008 Oct; 30(5):390-9. PubMed ID: 19046314
[TBL] [Abstract][Full Text] [Related]
36. [Auto-immune diseases and cancers. Second part: auto-immune diseases complicating cancers and their treatment].
Pasquet F; Pavic M; Ninet J; Hot A
Rev Med Interne; 2014 Oct; 35(10):656-63. PubMed ID: 25106665
[TBL] [Abstract][Full Text] [Related]
37. Relationship between autoantibody and dermatosis in myelodysplastic syndrome.
Shimamoto Y; Narisawa Y; Suga K; Yasutake T; Kohda H; Yamaguchi M
Haematologia (Budap); 1993; 25(4):253-61. PubMed ID: 8157207
[TBL] [Abstract][Full Text] [Related]
38. Vasculitis in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia: A Report of Two Cases.
Jacobse J; Sijpkens YWJ; van 't Wout JW; Peters EEM; Vlasveld LT
J Hematol; 2018 Dec; 7(4):158-162. PubMed ID: 32300432
[TBL] [Abstract][Full Text] [Related]
39. Defective cytotoxicity of T lymphocytes in myelodysplastic syndrome.
Cukrová V; Neuwirtová R; Dolezalová L; Belicková M; Bartůnková J; Jonásová A; Cermák J; Homolková H; Malíková I
Exp Hematol; 2009 Mar; 37(3):386-94. PubMed ID: 19136196
[TBL] [Abstract][Full Text] [Related]
40. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome.
Carlsten M; Baumann BC; Simonsson M; Jädersten M; Forsblom AM; Hammarstedt C; Bryceson YT; Ljunggren HG; Hellström-Lindberg E; Malmberg KJ
Leukemia; 2010 Sep; 24(9):1607-16. PubMed ID: 20613786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
